 CAMBRIDGE, Mass., March 12, 2021 GLOBE NEWSWIRE -- Rubius Therapeutics, Inc. Nasdaq: RUBY, a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell TherapeuticsTM, today announced that the Company plans to issue a pre-market press release and conduct a webcast on Monday, March 15, 2021, to discuss the initial clinical data findings from the ongoing Phase 12 trial of RTX-240 in patients with advanced solid tumors. 